Quick Answer: The Da Vinci 5 remains the dominant soft tissue surgical robot with 70%+ market share, while Mako leads orthopedic robotics at 85%+ share. Hugo RAS from Medtronic is the first credible multi-specialty challenger to Da Vinci, and Zimmer Biomet's ROSA serves the neurosurgery and spine niche. Your choice depends on specialty focus, case volume projections, and whether surgeon recruitment or cost efficiency is the primary driver.
The 2026 Surgical Robot Landscape
The surgical robotics market hit $8.2 billion in 2025 and is projected to reach $14 billion by 2028. Four platforms now account for over 90% of new installations in developed markets. Each serves different specialties, carries different economics, and demands different organizational commitments.
This comparison is designed for hospital administrators, surgical program directors, and CFOs evaluating capital investments. We focus on what matters for the buying decision: clinical coverage, total cost of ownership, surgeon adoption curves, and measurable ROI.
Head-to-Head Comparison
| Feature | Da Vinci 5 | Hugo RAS | Mako | ROSA | |---------|-----------|----------|------|------| | Manufacturer | Intuitive Surgical | Medtronic | Stryker | Zimmer Biomet | | System Price | $1.5-2.5M | $1.0-1.8M | $1.0-1.5M | $800K-1.2M | | Per-Procedure Cost | $2,000-3,500 | $1,200-2,200 | $800-1,500 | $600-1,000 | | Annual Service | $150-200K | $100-150K | $100-140K | $80-120K | | Specialties | Multi (soft tissue) | Multi (soft tissue) | Orthopedic | Neuro/Spine | | Installed Base | 9,000+ | 800+ | 5,000+ | 1,500+ | | Haptic Feedback | Yes (new in v5) | Yes | Yes | Limited | | FDA Clearances | 60+ procedures | 12+ procedures | 3 procedures | 4 procedures | | Training Timeline | 2-6 months | 2-4 months | 1-3 months | 1-2 months |
Da Vinci 5: The Market Leader
The Intuitive Da Vinci 5 is the fifth generation of the platform that created surgical robotics. With haptic feedback finally added in this generation, Intuitive has addressed the most persistent criticism from surgeons. The system supports 60+ cleared procedures across urology, gynecology, general surgery, thoracic, colorectal, and head and neck surgery.
Strengths
- Surgeon ecosystem. More surgeons are trained on Da Vinci than all competitors combined. This means faster recruitment and lower training friction.
- Multi-specialty utilization. A single system serving five surgical services can achieve 400+ cases per year, dramatically improving unit economics.
- Clinical evidence base. Over 15,000 peer-reviewed publications support Da Vinci outcomes across specialties.
Weaknesses
- Highest per-procedure costs. Proprietary instruments with 10-use limits create $2,000-3,500 per case in consumable costs — significantly higher than competitors.
- Vendor lock-in. Instruments, accessories, and service are all single-source, giving Intuitive significant pricing power.
Hugo RAS: The Credible Challenger
Medtronic's Hugo RAS entered the market as the first platform with a realistic chance of challenging Da Vinci in soft tissue surgery. Backed by Medtronic's $30 billion revenue base, global distribution, and existing surgical relationships, Hugo offers a modular architecture designed to be more cost-effective.
Strengths
- Lower consumable costs. Hugo's instrument economics run 30-40% below Da Vinci, saving $800-1,300 per procedure.
- Modular design. Individual robotic arms can be positioned independently, offering more flexibility in OR setup.
- Medtronic ecosystem. Integration with Touch Surgery for AI-powered surgical analytics and Medtronic's broader surgical portfolio.
Weaknesses
- Limited installed base. With only 800+ systems deployed, the surgeon training pipeline is still developing.
- Fewer cleared procedures. Hugo currently has 12+ FDA clearances compared to Da Vinci's 60+, limiting multi-specialty appeal.
Mako: Orthopedic Dominance
The Stryker Mako system has become synonymous with robotic joint replacement. Using preoperative CT scans to create 3D bone models, Mako provides haptic-guided bone preparation that consistently delivers superior implant positioning accuracy.
Strengths
- Clinical outcomes. Studies show 40-50% reduction in positioning outliers and lower revision rates at 5-year follow-up.
- Patient acquisition tool. Robotic joint replacement is a powerful marketing differentiator — patients actively seek it out.
- Fastest ROI. High case volumes in orthopedics (a hospital's most profitable service line) can deliver payback in 18-24 months.
Weaknesses
- Single specialty. Mako is limited to total knee, total hip, and partial knee arthroplasty. No expansion to soft tissue.
- CT requirement. Every patient needs a preoperative CT scan, adding $200-400 and workflow complexity.
ROSA: The Neurosurgery Specialist
Zimmer Biomet's ROSA platform serves neurosurgery and spine — high-acuity, lower-volume specialties where robotic precision delivers disproportionate value. The system guides electrode placement in deep brain stimulation, assists with pedicle screw placement in spine fusion, and supports stereotactic biopsy.
Strengths
- Lowest total cost. System price under $1.2M with modest per-procedure costs makes ROSA accessible to mid-size hospitals.
- Precision in high-stakes procedures. Sub-millimeter accuracy in brain surgery, where errors measured in millimeters can mean paralysis or worse.
- Growing spine application. Robotic-assisted pedicle screw placement is one of the fastest-growing surgical robotics applications.
Weaknesses
- Low case volumes. Neurosurgery and spine cases are inherently lower volume than general surgery or orthopedics, extending ROI timelines.
- Limited competitive moat. Globus Medical's ExcelsiusGPS and Brainlab are competitive alternatives in spine.
Total Cost of Ownership: 5-Year Analysis
The purchase price is misleading. Here is what each platform actually costs over five years at moderate utilization (250 cases per year for soft tissue, 300 for orthopedic, 150 for neuro/spine):
| 5-Year TCO | Da Vinci 5 | Hugo RAS | Mako | ROSA | |------------|-----------|----------|------|------| | System | $2,000,000 | $1,400,000 | $1,250,000 | $1,000,000 | | Consumables | $3,437,500 | $2,125,000 | $1,725,000 | $600,000 | | Service | $875,000 | $625,000 | $600,000 | $500,000 | | Training | $200,000 | $150,000 | $100,000 | $75,000 | | Total | $6,512,500 | $4,300,000 | $3,675,000 | $2,175,000 | | Per Case | $5,210 | $3,440 | $2,450 | $2,900 |
Use the TCO Calculator to model costs for your specific case volume and specialty mix.
Decision Framework
Choose Da Vinci 5 if:
- You need multi-specialty coverage across 3+ surgical services
- Surgeon recruitment and retention is a primary strategic goal
- You project 300+ cases per year to justify the premium economics
Choose Hugo RAS if:
- Cost efficiency is the priority and you are building a new program
- You are already a Medtronic surgical customer and value ecosystem integration
- You are comfortable with a newer platform and smaller peer community
Choose Mako if:
- Orthopedic volume is your primary growth strategy
- Total joint replacement is a competitive battleground in your market
- You want the fastest path to measurable ROI
Choose ROSA if:
- You are building or expanding a neurosurgery or spine program
- Case volumes are modest but procedure complexity is high
- Budget constraints preclude a $2M+ capital investment
The Multi-Platform Reality
Most large health systems in 2026 operate two or more surgical robot platforms. The typical combination is Da Vinci (or Hugo) for soft tissue plus Mako for orthopedics. ROSA adds a third platform for systems with active neurosurgery programs. The incremental capital is significant, but the alternative — telling your spine surgeon or orthopedic chief that robotics is not in the budget — carries its own cost in recruitment and market share.
Use the Robot Finder to explore surgical robot options matched to your hospital's specialty mix and volume projections.